- Home
- CGEM vs ERAS Comparison
CGEM vs ERAS Comparison
Compare CGEM & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGEM
- ERAS
- Stock Information
- Founded
- CGEM 2016
- ERAS 2018
- Country
- CGEM United States
- ERAS United States
- Employees
- CGEM N/A
- ERAS N/A
- Industry
- CGEM Biotechnology: Pharmaceutical Preparations
- ERAS Biotechnology: Pharmaceutical Preparations
- Sector
- CGEM Health Care
- ERAS Health Care
- Exchange
- CGEM Nasdaq
- ERAS Nasdaq
- Market Cap
- CGEM 730.2M
- ERAS 723.8M
- IPO Year
- CGEM 2021
- ERAS 2021
- Fundamental
- Price
- CGEM $11.87
- ERAS $2.48
- Analyst Decision
- CGEM Strong Buy
- ERAS Strong Buy
- Analyst Count
- CGEM 7
- ERAS 5
- Target Price
- CGEM $31.67
- ERAS $5.90
- AVG Volume (30 Days)
- CGEM 514.5K
- ERAS 1.4M
- Earning Date
- CGEM 11-07-2024
- ERAS 11-12-2024
- Dividend Yield
- CGEM N/A
- ERAS N/A
- EPS Growth
- CGEM N/A
- ERAS N/A
- EPS
- CGEM N/A
- ERAS N/A
- Revenue
- CGEM N/A
- ERAS N/A
- Revenue This Year
- CGEM N/A
- ERAS N/A
- Revenue Next Year
- CGEM N/A
- ERAS N/A
- P/E Ratio
- CGEM N/A
- ERAS N/A
- Revenue Growth
- CGEM N/A
- ERAS N/A
- 52 Week Low
- CGEM $9.24
- ERAS $1.64
- 52 Week High
- CGEM $30.19
- ERAS $3.45
- Technical
- Relative Strength Index (RSI)
- CGEM 41.20
- ERAS 39.81
- Support Level
- CGEM $10.44
- ERAS $2.38
- Resistance Level
- CGEM $12.79
- ERAS $2.59
- Average True Range (ATR)
- CGEM 0.67
- ERAS 0.18
- MACD
- CGEM 0.03
- ERAS -0.05
- Stochastic Oscillator
- CGEM 45.25
- ERAS 12.50
About CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, create differentiated ideas, identify the appropriate targets, and select the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.